Q-omics provides the consensus-scored CRYZL1 profile across patient tissues and cancer cell-line models. CRYZL1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CRYZL1 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, CRYZL1 protein abundance shows 23,979 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, THCA, and PDAC as cancer lineages where CRYZL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRYZL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRYZL1 survival associations across molecular data types. CRYZL1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRYZL1 RNA expression–survival associations across cancer types. High CRYZL1 expression shows unfavorable associations in SCLC, HNSC and ACC, but favorable associations in KIRC, BRCA and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CRYZL1 RNA expression.
This table summarizes CRYZL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for CRYZL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRYZL1 shows lower tumor expression in THCA, KICH, UCEC, LUAD and LUSC and higher tumor expression in LIHC. The THCA box plot shows higher CRYZL1 RNA expression in normal versus tumor tissue (log2 FC = −0.358, t-test p < 0.001).
This table shows molecular features associated with CRYZL1 in patient tissues and cancer cell lines. In patient samples, CRYZL1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, CRYZL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
